Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF8, SGN-35(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14764MR)

This product GTTS-WQ14764MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets TNFRSF8 gene. The antibody can be applied in Anaplastic large cell lymphoma (ALCL), Hodgkin lymphoma research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001243.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 943
UniProt ID P28908
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF8, SGN-35(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ14764MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3756MR IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BAY-1834942
GTTS-WQ11901MR IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MLN-1202
GTTS-WQ6235MR IVTScrip™ mRNA-Anti-RABVgp4, CR57(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CR57
GTTS-WQ15388MR IVTScrip™ mRNA-Anti-CD37, TRU-016(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA TRU-016
GTTS-WQ5345MR IVTScrip™ mRNA-Anti-CD38, CD38-Attenukine(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CD38-Attenukine
GTTS-WQ11734MR IVTScrip™ mRNA-Anti-IGF1R, MK-0646(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MK-0646
GTTS-WQ15470MR IVTScrip™ mRNA-Anti-MAPT, UCB-0107(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA UCB-0107
GTTS-WQ3045MR IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA Anti-PTK7 ADC
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW